Causes & What We Know/October 26, 2026/3 min read

Understanding the Immune System's Role in Type 1 Diabetes

Type 1 diabetes involves multiple types of immune cells working together to attack insulin-producing cells. New research is revealing how these immune processes work—and opening doors to better treatments.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

causesautoimmunitygeneticsrisk

Key takeaways

T cells are central to Type 1 diabetes, but many other immune cells—including dendritic cells, macrophages, and natural killer cells—also play important roles in initiating and sustaining the autoimmune attack.
Both helper T cells and cytotoxic T cells damage insulin-producing beta cells through inflammatory signals and direct attack, while protective regulatory T cells are reduced or weakened in people with Type 1 diabetes.
Advanced research tools like single-cell analysis and T cell receptor sequencing are helping scientists understand which specific immune cells target the pancreas and why.
Immune signatures are emerging as potential tools to predict who may develop Type 1 diabetes and to identify which patients might benefit from specific treatments.
Several therapeutic approaches—including monoclonal antibodies, tolerogenic vaccines, and regulatory T cell therapies—are moving from laboratory research into clinical testing.

What Happens in Type 1 Diabetes

Type 1 diabetes develops when the immune system mistakenly attacks beta cells—the insulin-producing cells in the pancreas. This autoimmune response eventually destroys enough beta cells to cause lifelong insulin dependence. Understanding exactly how and why this happens is central to developing new treatments.

For years, researchers focused primarily on T cells, a type of white blood cell that plays a direct role in the attack on beta cells. But the picture is far more complex than T cells alone.

Multiple Immune Players in the Attack

Recent research shows that innate immune cells—which are part of the body's first-line defense system—are just as important as T cells in triggering and sustaining beta cell damage. Dendritic cells, macrophages, and natural killer cells all contribute to initiating and shaping the autoimmune response within the pancreas.

Two main types of T cells participate in beta cell destruction. Helper T cells (CD4+) and cytotoxic T cells (CD8+) injure beta cells through multiple mechanisms: they produce inflammatory molecules, directly kill the cells, and break down the body's normal self-tolerance. At the same time, regulatory T cells—which normally act as a brake on autoimmunity—are either reduced in number or don't function properly in people with Type 1 diabetes, allowing the attack to accelerate unchecked.

New Tools, Better Understanding

Scientists now have powerful new technologies to study how these immune attacks unfold. Single-cell transcriptomics allows researchers to examine individual immune cells and their behavior. Spatial immune profiling reveals where different immune cells are located within the pancreas. T cell receptor sequencing helps identify which specific autoreactive immune cells are present and attacking beta cells.

These advances are refining scientists' understanding of autoreactive repertoires—the specific populations of immune cells attacking the pancreas—and how innate and adaptive immune systems communicate and influence each other.

From Research to Clinical Treatment

As basic research clarifies the immune mechanisms underlying Type 1 diabetes, immune signatures—distinctive patterns in blood or tissue that reflect immune activity—are emerging as tools for disease prediction and for matching patients to appropriate treatments.

Several therapeutic strategies are advancing from laboratory development into human clinical trials. These include monoclonal antibodies (like teplizumab, which has already shown clinical benefit), tolerogenic vaccines designed to reduce autoimmunity, and adoptive regulatory T cell therapies that restore immune balance. The clinical success of teplizumab as a disease-modifying therapy demonstrates that targeting specific immune pathways can make a meaningful difference, while ongoing research aims to develop treatments that achieve more durable improvements.

Evidence label

Source: Frontiers in immunology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.